NeoChord, Inc. specializes in innovative technologies aimed at addressing heart valve disease, particularly mitral valve repair. The company has developed a proprietary device known as the NeoChord DS1000, which utilizes a unique approach to restore the function of the mitral valve. This device is designed to be minimally invasive, allowing for a more efficient surgical procedure that can lead to quicker recovery times for patients. The NeoChord DS1000 employs a technique that involves the use of artificial chordae to replace the damaged or elongated chordae tendineae, which are critical for the proper functioning of the mitral valve.

In addition to the NeoChord DS1000, the company is focused on advancing its technology through ongoing research and development. NeoChord is committed to improving patient outcomes by refining its devices and exploring new applications within the field of cardiac surgery. The emphasis on minimally invasive techniques not only enhances the surgical experience but also aims to reduce the overall burden of heart valve disease on patients and healthcare systems. Through its innovative solutions, NeoChord, Inc. is positioned to make significant contributions to the treatment of mitral valve disorders.

United States

NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.

NeoChord, Inc.

Company Details